Overview


According to FutureWise analysis, the market for Real-world Evidence Analytics is expected to grow with a CAGR of 15.1% over the forecast period 2024-2032, and reach a market value of US$ 3.88 Billion by 2031. 

Real-world Evidence (RWE) Analytics constitutes a pivotal component of modern healthcare research and decision-making. It systematically analyzes health data from real-world clinical settings, encompassing various sources like electronic health records, claims data, patient registries, and wearable devices. Unlike data obtained from controlled clinical trials, RWE reflects the complexities and nuances of actual patient experiences, treatment patterns, and healthcare utilization. This treasure trove of information provides invaluable insights into how therapies and interventions perform in real-world scenarios, shedding light on their effectiveness, safety, and economic impact.

One of the critical strengths of RWE Analytics is its capacity to inform healthcare decisions holistically and comprehensively. It considers many variables, including patient demographics, comorbidities, treatment adherence, and clinical practice variations. This breadth of data allows for a deeper understanding of how treatments work in diverse patient populations, facilitating more personalized and effective healthcare strategies. Moreover, RWE Analytics is increasingly recognized for complementing traditional clinical trial data. It serves as a crucial source of evidence for regulatory agencies, payers, and healthcare providers, especially in scenarios where conducting large-scale clinical trials is impractical or ethically challenging.

FutureWise Market Research has published a report that provides an insightful analysis of Real-world Evidence Analytics Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Real-world Evidence Analytics Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Clinigen Group plc 
  • ICON plc 
  • IQVIA Holdings Inc. 
  • Oracle Corporation 
  • Parexel International Corporation 
  • PerkinElmer, Inc. 
  • PPD Inc. 
  • SAS Institute Inc. 
  • UnitedHealth Group Incorporated
  • Flatiron Health 

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Real-world Evidence Analytics Market:

  • In August of 2022, Trinity Life Sciences in the United States revealed a strategic collaboration with Bain & Company, aiming to combine Bain & Company's extensive expertise in the Life Sciences value chain with the evidence-driven solutions offered by Trinity Life Sciences.
  • Similarly, in July 2022, TriNetX LLC unveiled a partnership with Pediatric Medical Centers in the United States, which includes renowned institutions like Children's National Hospital, WVU Medicine Children's, and John Hopkins All Children Hospitals. The collaboration aims to enhance investor-initiated research by utilizing real-world pediatric data.

The shift towards value-based healthcare models emphasizes the importance of real-world evidence in demonstrating the effectiveness and value of treatments and interventions in real-world clinical settings. The trend towards personalized medicine requires robust RWE analytics to understand how treatments perform in specific patient populations, accounting for factors like genetic variations, comorbidities, and lifestyle driving the market growth. The widespread adoption of EHR systems provides a rich source of structured clinical data that can be leveraged for real-world evidence generation and analysis. Innovations in data analytics, machine learning, and artificial intelligence enhance the capabilities to analyze and derive meaningful insights from large volumes of real-world data, propelling market growth.

However, ensuring the quality, completeness, and standardization of real-world data remains challenging due to the diverse sources and varying data accuracy and completeness levels. Safeguarding patient privacy and complying with data protection regulations (e.g., GDPR) can be complex when working with sensitive healthcare data. Real-world data may be subject to various biases, such as selection bias or confounding variables. Ensuring the generalizability of findings from RWE studies is a challenge.

By Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Regulatory and Clinical Decision-making

By End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to a rise in the number of clinical trials, increasing government initiatives for the adoption of RWE studies, increasing demand for better healthcare services, increasing incidence of chronic illness, and rising geriatric population are contributing in the market growth in this region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Real-world Evidence Analytics Market By Application, By End User, and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1 Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3.Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Real-world Evidence Analytics Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Real-world Evidence Analytics Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Real-world Evidence Analytics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Real-world Evidence Analytics Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Market Access & Reimbursement/Coverage Decisions
      2. Drug Development & Approvals
      3. Oncology
      4. Neurology
      5. Immunology
      6. Cardiovascular Diseases
      7. Other Therapeutic Areas
      8. Post Market Surveillance
      9. Medical Device Development & Approvals
      10. Regulatory and Clinical Decision-making
         
  • 8.  Real-world Evidence Analytics Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
      1. Pharmaceutical, Biotechnology, and Medical Device Companies
      2. Healthcare Payers
      3. Healthcare Providers
      4. Other End Users
         
  • 9.  North America Real-world Evidence Analytics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 10.  Latin America Real-world Evidence Analytics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 11.  Europe Real-world Evidence Analytics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 12.  Asia Pacific Real-world Evidence Analytics Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032

  • 13.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 14.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 15.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)
    •   1. Clinigen Group plc (U.K.)
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. ICON plc (Ireland)
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. IQVIA Holdings Inc. (U.S.)
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. Oracle Corporation (U.S.)
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Parexel International Corporation (U.S.)
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. PerkinElmer, Inc. (U.S.)
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. PPD Inc. (U.S.)
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. SAS Institute Inc. (U.S.)
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. UnitedHealth Group Incorporated (U.S.)
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Flatiron Health (U.S.)
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview

  • 16.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
            administrations
        5. The overall economic slowdown of the developing and developed nations

  • 17.  FutureWise SME Key Takeaway Points for Client
    •   

Partner

Our Clients